
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PDGF-B CRISPR/Cas9 KO Plasmid (h) | sc-400586 | 20 µg | $397.00 |
PDGFB encodes platelet-derived growth factor subunit B (PDGF-B), a secreted mitogen that forms active PDGF dimers and signals primarily through PDGF receptor tyrosine kinases to regulate pericyte recruitment, vascular maturation, and mesenchymal cell proliferation. PDGF-B–driven signaling engages MAPK/ERK, PI3K–AKT, and PLCγ pathways, shaping cytoskeletal remodeling, chemotaxis, and extracellular matrix deposition in stromal and vascular compartments. Dysregulated PDGFB expression or PDGF axis activation is implicated in pathological angiogenesis, fibrotic remodeling, and PDGF-dependent autocrine or paracrine growth circuits observed across diverse tumor microenvironments. As a result, PDGFB is widely studied in endothelial–pericyte communication, wound repair biology, and stromal signaling networks relevant to tissue remodeling and cancer biology.
PDGF-B CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PDGFB gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PDGFB together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PDGFB open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PDGF-B protein expression.
This CRISPR knockout system enables efficient generation of PDGFB-deficient cell models for investigation of PDGF-B signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.